Company intelligence / Profile preview

Elixir Group

Cambridge, Massachusetts, United Stateselixirgroup.rs ↗

Ownership: Private
Development stage: Other

Overview

Elixir Pharmaceuticals was a Cambridge-based biopharmaceutical company developing drugs targeting metabolic and age-related diseases using genomics-driven approaches. The company raised over $169M but ultimately ceased operations ("Dead" status). It filed patents around cytochrome c acetylation and longevity gene modulation but did not bring products to market.

Therapeutic areas: Metabolic DisordersOther
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Evotec OAI for chemical/biological drug discovery services under an alliance with Oxford Bioscience Partners portfolio companies.

Beyond the preview

Go deeper on Elixir Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elixir Group.

Explore the full profile